Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9200
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheng, Chao-Neng-
dc.contributor.authorLi, Sin-Syue-
dc.contributor.authorYeh, Yun-Hsuan-
dc.contributor.authorShen, Ching-Fen-
dc.contributor.author-Shiuh Chen, Jiann-
dc.date.accessioned2024-12-18T02:36:45Z-
dc.date.available2024-12-18T02:36:45Z-
dc.date.issued2022-04-01-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9200-
dc.description.abstractAbstract From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis. Three children, none of whom received prophylaxis, experienced cytomegalovirus reactivation. Letermovir is a promising medication for use in cytomegalovirus prophylaxis in children. Further studies are warranted.en_US
dc.language.isoenen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectChildren;en_US
dc.subjectCytomegalovirus;en_US
dc.subjectHematopoietic stem cell transplantation;en_US
dc.subjectLetermovir;en_US
dc.subjectProphylaxisen_US
dc.titleLetermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwanen_US
dc.typeArticleen_US
Appears in Collections:VOL 55 NO 2 2022

Files in This Item:
File Description SizeFormat 
323-327.pdf668.2 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.